https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/issue/feedBiomedical Sciences and Clinical Medicine2024-12-16T14:05:47+07:00Pornngarm Dejkriengkraikul, PhDpornngarm.d@cmu.ac.thOpen Journal Systems<table style="table-layout: fixed;" border="0" width="100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="ST09" valign="top" width="60" height="30"> <p style="font-size: 12px;">Welcome to the Biomedical Sciences and Clinical Medicine (BSCM). It is with great pleasure that I invite you to explore our journal, where we are committed to fostering a culture of inclusivity and scientific excellence. At BSCM, our mission is to advance biomedical knowledge and clinical practice. We are dedicated to bridging the gap between research and clinical application, ensuring that innovative discoveries translate into practical benefits for patients and healthcare systems worldwide. Our journal serves as a hub for multidisciplinary collaboration, bringing together researchers, clinicians, and scholars from around the world. Here, groundbreaking research and pioneering ideas are exchanged, driving forward the progress of medical science.</p> <p style="font-size: 12px;">We are proud to have achieved international recognition, with BSCM now indexed in the SCOPUS database, including all manuscripts from 2022 onwards. We currently have over 64 documents indexed in SCOPUS, covering issues from Vol. 61 No. 1 (2022) to the present. In response to the growing number of high-quality submissions, we have increased the number of articles published per issue from 6 to 8. Additionally, we have updated our Editorial Team for the 2024-2027 term, bringing together esteemed professionals whose expertise and dedication are integral to advancing the fields of biomedical and clinical sciences. There insights and commitment will undoubtedly enhance the scholarly impact of BSCM.</p> <p style="font-size: 12px;">I warmly invite you to consider submitting your work to BSCM. We welcome original articles, review articles, case reports, and short communications. Even brief laboratory work that offers significant new findings is valued. Whether you are an experienced practitioner, an innovative researcher, or someone eager to explore the frontiers of medical knowledge, we extend a warm invitation to join us on this enlightening journey. Please take note of our updated “Submission Checklist” in the Author Guidelines to ensure your manuscript meets our standards. </p> <p style="font-size: 12px;">Thank you for your interest in BSCM. We look forward to your continued support and contribution to the ever-evolving landscape of biomedical and clinical research.</p> </td> <td class="HL10" width="5"> </td> <td class="ST07 " valign="Top" width="30" height="30"> <p><img src="https://he01.tci-thaijo.org/public/site/images/cmmj_medcmu2/bscm-cover-for-web-issn-01-2e4b55ddf320ce72403844d1346a6343.jpg" alt="" width="213" height="301" /></p> </td> </tr> </tbody> </table> <table> <tbody> <tr> <td style="font-size: 12px;" colspan="2"><strong>Biomedical Sciences and Clinical Medicine (BSCM)</strong></td> </tr> <tr> <td style="font-size: 12px;"><strong>Journal Abbreviation:</strong></td> <td style="font-size: 12px;">Biomed. Sci. Clin. Med.</td> </tr> <tr> <td style="font-size: 12px;"><strong>Online ISSN:</strong></td> <td style="font-size: 12px;">2774-1079</td> </tr> <tr> <td style="font-size: 12px;"><strong>Start year:</strong></td> <td style="font-size: 12px;">2022 Biomedical Sciences and Clinical Medicine, Current name</td> </tr> <tr> <td> </td> <td style="font-size: 12px;">2010 Chiang Mai Medical Journal, old name</td> </tr> <tr> <td> </td> <td style="font-size: 12px;">1961 Chiang Mai Medical Bulletin, old name</td> </tr> <tr> <td style="font-size: 12px;"><strong>Language: </strong></td> <td style="font-size: 12px;">English</td> </tr> </tbody> </table> <p style="font-size: 12px;"> </p> <p><img src="https://he01.tci-thaijo.org/public/site/images/cmmj_medcmu2/s--35389477-de7b01b01b00898657a612eab674218b.jpg" alt="" width="200" height="199" /></p> <p style="font-size: 12px;"><strong>Editor-in-Chief:</strong> <a href="https://www.scopus.com/authid/detail.uri?authorId=6602093623" target="_blank" rel="noopener">Pornngarm Dejkriengkraikul, Ph.D.</a> <br />Professor, Faculty of Medicine, Chiang Mai University, Thailand</p>https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/271545Feasibility of Large Multi-Leaf Collimator in Stereotactic Radiosurgery/Stereotactic Radiotherapy: A Single Center Experience2024-07-26T08:58:21+07:00Akanit Chaiyapongakanit_ch@cmu.ac.thAnirut Watcharawiphaanirut.watch@cmu.ac.thWannapha Nobnopwannapha.n@cmu.ac.thAnupong Kongsaanupong.k@cmu.ac.thBongkot Jia-Mahasapphung_nemo@hotmail.com<p><strong>Objective</strong> This study investigated the feasibility of using a large multi- leaf collimator (MLC) in a C-arm based linear accelerator for stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT).</p> <p><strong>Methods </strong>Patient Specific Quality Assurance was conducted on 69 patients treated with a single lesion SRS/SRT measuring dose distribution using patient-specific plans with SRS MapCHECK<sup>®</sup>. Statistics were used to analyze the significance of correlation among dosimetric parameters, included Conformity Index (CI), Gradient Index (GI), plan complexity, and Gamma passing rate (GPR) in an absolute dose (AD) and relative dose (RD). confidence limit (CL) was also calculated to evaluate the performance of a large multileaf collimator (MLC) in SRS/SRT.</p> <p><strong>Results </strong>Planning target volumes (PTVs) ranged between 0.34 cm<sup>3</sup> and 30.42 cm<sup>3</sup>. The study found a value of CI<sub>ICRU</sub>, CIPaddick, and GI of 1.29 ± 0.17, 0.77±0.10 and 5.24±2.18 (mean±SD), respectively, significant correlations were found between PTV sizes and dosimetric parameters. Values of GPR<sub>2</sub><sub>%/</sub><sub>2mm</sub> were 92.42±3.74 (AD), 96.38±3.24 (RD), whereas GPR<sub>2</sub><sub>%/</sub><sub>1mm </sub>were 82.03±6.69 (AD), 89.64±7.26 (RD). No significant correlation was found between plan complexity and GPR. CL values were 85.09% (AD), 90.03% (RD) for GPR<sub>2</sub><sub>%/</sub><sub>2mm</sub> and 68.92% (AD), 75.41% (RD) for GPR2<sub>%/</sub><sub>1mm</sub><sub>.</sub> </p> <p><strong>Conclusions </strong>This study assessed the feasibility of using a large MLC for a single lesion SRS/SRT across various PTV sizes. The values of CI and GI decreased for a small lesion. While the large MLC performed adequately across different PTV sizes, the CL value of RD GPR at 2%/1 mm fell below 90%. This indicates that the contribution of PTV margin might be consi-dered for a large MLC in SRS/SRT</p>2024-12-16T00:00:00+07:00Copyright (c) 2024 https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/271857The Relationship between Hyperuricemia and Anemia in Postmenopausal Korean Women2024-09-19T12:38:54+07:00Hyun Yoonyh9074@yahoo.co.krSun Gyu Kimsun1590kr@dongnam.ac.krMi Young Gikmy1464@naver.comJu Ae Chack1093@nate.comSo Young Park1101soyoung@naver.comCho Hee Parkend121500@naver.comHyun Ho Sungwantyou7@dongnam.ac.krEun Sook Hanyeshan0679@naver.com<p><strong>Objective</strong> The present study was conducted to assess the association of hyperuricemia and anemia in premenopausal and postmenopausal Korean women.</p> <p><strong>Methods</strong> Data from 9,239 adults (aged ≥ 20 years) in the Korean National Health and Nutrition Examination Survey VII (2016–2018) were analyzed.</p> <p><strong>Results</strong> After adjustment for related variables (including age), the odds ratio (OR) of hyperuricemia (uric acid [UA] < 6.0 mg/dL), using the normal group (hemoglobin [Hb] ≥ 12.0 g/dL) as a reference, was statistically significantly positively associated with the anemia group (Hb < 12.0 g/dL) in postmenopausal women (OR, 1.615; 95% CI, 1.187–2.198). In premenopausal women, after adjustment for the related variables (except age), the OR of hyperuricemia, with a normal group as a reference, was significantly inversely associated with the anemia group (OR, 0.583; 95% CI, 0.348–0.975). However, with further adjustment for age, hyperuricemia was no longer associated with anemia (OR, 0.679; 95% CI, 0.402–1.148).</p> <p><strong>Conclusions</strong> Hyperuricemia is positively associated with anemia in postmenopausal women but not in premenopausal women. </p>2024-12-16T00:00:00+07:00Copyright (c) 2024 https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/271159Predicting Hospital Admission of Patients at Triage in the Emergency Department at Lampang Hospital2024-07-26T09:48:54+07:00Noppadon Seesuwannoppadon_kim@yahoo.comThanin Lokeskraweeno@email.comSuppachai Lawanaskolno@email.comJayanton Patumanondno@email.com<p><strong>Objective</strong> This study aims to develop a model that can help predict the likelihood of hospital admission for patients at the triage point in Lampang Hospital’s Emergency Department.</p> <p><strong>Methods </strong>The study was designed around Clinical Prediction Rules and was conducted as a retrospective cohort study using data from July 2021 to January 2022 input through the Smart ER program. Patients were categorized into two groups: admit and discharge. Statistical <br />analysis involved both univariable and multivariable logistic regression analyses, presenting discrimination values with area under the receiver operating characteristic (AUROC), testing precision with a calibration plot, analyzing internal validation using the Bootstrapping method, and creating a risk curve to find the balanced cutoff point. The study then divided the predictions into one of three groups: Admit, Consult, and Discharge. Decision curve analysis (DCA) was performed and an application was developed and integrated into the Smart ER program for real- time analysis.</p> <p><strong>Results </strong>Out of 37,474 patients screened, 18,056 were excluded leaving 19,418 patients eligible for complete case analysis. Predictors of hospital admission included age, emergency level, vital signs, mode of hospital arrival, and prominent symptoms according to criteria-based dispatch (CBD) (criteria-based dispatch). The Admission Model showed an AUROC of 0.8934 (95% CI, 0.8890-0.8980); the calibration plot demonstrated that predicted values closely matched actual observed values; internal validation using the Bootstrapping method yielded a C-statistic of 0.8920 (95% CI, 0.888-0.895); and the balanced risk curve indicated over admission at 3.8% and over discharge at 3.7%.</p> <p><strong>Conclusions </strong>The Admission Model provides high AUROC and precision values. The model’s three-group division is likely to be beneficial in practical application. </p>2024-12-18T00:00:00+07:00Copyright (c) 2024